[144] Cardlytics, Inc. SEC Filing
Rhea-AI Filing Summary
Cardlytics, Inc. (CDLX) filed a Form 144 notice reporting a proposed sale of 68,260 common shares through Fidelity Brokerage Services with an aggregate market value of $76,806.15. The filing lists the number of shares outstanding as 53,236,901 and indicates an approximate sale date of 08/18/2025 on NASDAQ. The securities were acquired as restricted stock vesting from the issuer on 08/15/2025 and the payment nature is noted as compensation.
The filer also reported a prior sale on 07/02/2025 of 6,725 shares for gross proceeds of $11,987.99. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
Positive
- None.
Negative
- None.
Insights
TL;DR This Form 144 reports a routine officer/insider sale of vested restricted stock with no additional disclosures.
The notice documents a proposed sale of 68,260 common shares via Fidelity with an aggregate market value of $76,806.15 and notes a prior sale of 6,725 shares for $11,987.99. The shares were acquired as restricted stock vesting from the issuer and the filing contains the required attestation about material non-public information. The filing does not disclose any earnings, financing, litigation, or other events beyond the equity sales themselves.
TL;DR The filing is a standard insider sale notice tied to vested compensation; it contains no governance irregularities or additional disclosures.
The Form 144 lists the transaction details, broker, acquisition method (restricted stock vesting), and the seller's attestation regarding material information. No departures from standard disclosure practices are indicated within the notice.